Founded in 2008 and headquartered in Shenzhen, China, YHLO is a rapidly growing IVD company. Listed on the Shanghai Stock Exchange since 2021, YHLO invests heavily in R&D and collaborates with leading institutions worldwide. It offers advanced immunoassay instruments and solutions, covering areas like fertility, diabetes, and infectious diseases. Certified under ISO and international standards, YHLO operates in nearly 100 countries and partners globally to drive innovation, enhance diagnostics, and improve healthcare outcomes across the world.